REDVET - Revista electrónica de Veterinaria - ISSN 1695-7504
Vol 25, No. 1 (2024)
http://www.veterinaria.org
Article Received: Revised: Accepted:

The Proliferation And Impact Of Clandestine Drug Laboratories In India

Shilpa Kaushik[1], Mithlesh Jani[2,*], Chhote Raja Patle[2], Thakur Shruti Singh[1]

[1]Assistant Professor, Department of Forensic Science, Mandsaur University, Mandsaur (M.P.) India
[2*]Assistant Professor, Department of Forensic Science, Medi-Caps University, Indore (M.P.) India,
*mithleshhjani@gmail.com

ABSTRACT
The rise of clandestine drug laboratories in India represents a significant and growing threat to public health, safety, and the environment. This study examines the historical context and current landscape of these illegal operations, highlighting their proliferation and the factors contributing to their growth. Utilizing secondary data from sources such as the United Nations Office on Drugs and Crime (UNODC) and regional newspapers, the research analyzes trends in the distribution and production of various illicit substances. Key findings reveal a predominance of heroin and methamphetamine production, with significant impacts on both human health and the environment due to the hazardous waste generated by these labs. The study also evaluates the effectiveness of government responses and enforcement strategies, identifying challenges such as regulatory loopholes, corruption, and the need for better inter-agency coordination. Policy recommendations are proposed to enhance regulatory measures, improve law enforcement capabilities, and mitigate the socio-economic drivers of illicit drug production. This comprehensive analysis aims to inform policymakers and public health officials, contributing to the development of more effective strategies to combat the clandestine drug industry in India.

Keywords: clandestine drug laboratories; public health; environmental impact; law enforcement; policy recommendations

Introduction

The word ‘Clandestine’ simply refers to ‘done in secret’ most likely to conceal an illicit or illegal/improper act (Al-Obaidi & Fletcher, 2014). Here we concern about ‘Drug Clandestine laboratories’ therefore it refers to the illegal production of controlled substances. If we talk about legalities, an individual must be registered as a manufacturer of the controlled drug substances by the authorities in charge of drug control in the states and must follow strict guidelines in accordance with controlled substance Act (India, n.d.).

Clandestine Drug Laboratories are defined as the site (it may be an apartment, house premises, hotel rooms, obsolete industrial site, and all types of vehicles) where illegal production or synthesis of drugs or drug precursors occur by using improvised materials (common household equipment such as; stoves, hot plates, microwave ovens, pots, pans, trash bags, plastic bottles, jars, electric skillets etc.) and methods also (Man, Stoeber, Walus, & Columbia, 2008). These are small scale and secretly running chemical manufacturing laboratories, handle by the criminal element also involving the supply of these illegal or controlled substances. The clandestine laboratories as the name indicate does not have any check on standards of the products manufactured, no safety system (Buchanan & Brown, 1988). There is huge amount of toxic waste is produced during manufacturing of illegal substances in such illegal setups and this toxic waste along with equipment wastes haphazardly disposed of in public premises such as parks, vacant lots, waterways and fields etc. This is the reason that the products and by- products of these kind of labs affect not only human health but also the environment (Copes & Dods, 2006). Both chronic and acute effects of such substances were observed. There are several health hazards associated with such substances (Wright, Edwards, & Walker, 2016).

The proliferation of clandestine laboratories in India is a burgeoning issue that mirrors a global trend in the illegal production of narcotics and synthetic drugs. These covert operations are instrumental in the manufacturing of substances such as methamphetamine, synthetic opioids, and other illicit drugs (Lyman, 2016). The existence and expansion of these laboratories pose significant threats to public health, law enforcement, and national security.

India has long been recognized for its robust pharmaceutical and chemical industries, which contribute significantly to its economy (Chiu, Leclerc, & Townsley, 2011). However, this industrial strength has also provided a foundation for the rise of clandestine drug laboratories. These illegal operations exploit the country's extensive chemical production capabilities and the occasional lapses in regulatory oversight (Lalitha, 2002). Historically, while India has been a legitimate producer of precursor chemicals and pharmaceuticals, the illegal redirection of these substances for drug manufacturing has become increasingly problematic (Broadhurst, 2018).

The current landscape is characterized by a noticeable increase in the discovery and dismantling of these clandestine laboratories. Accurately assessing the full extent of clandestine laboratory operations in India is challenging due to their covert nature. Nevertheless, the periodic raids and seizures by law enforcement provide some insights.

Several, interrelated factors contribute to the rise of clandestine laboratories in India. Firstly, India's geographical position makes it a strategic point in the global drug trafficking network, situated between the Golden Crescent and the Golden Triangle, two major drug-producing regions (Biswas & Biswas, 2008). Secondly, the availability of precursor chemicals,

essential for synthesizing various narcotics, is relatively unregulated in some regions, facilitating their diversion into illegal channels (Buxton, 2008). Thirdly, socio-economic factors such as poverty, unemployment, and lack of education drive individuals toward illicit activities, including drug manufacturing (Singer, 2008). Lastly, corruption and bureaucratic inefficiencies within enforcement agencies hinder effective policing and regulatory enforcement.
Some of the main products of clandestine Drug Laboratories (CDL) are Amphetamines, MDMA (ecstasy), Methcathinone, PCP, LSD, and Fentanyl, from which one of the most commonly manufactured substance is methamphetamine because its precursors like ephedrine and pseudoephedrine are legally manufacture and traded in the country in significant amount (Laura Bruck, 2007). In 1919, Japanese first synthesized the 'meth' and prescribed it to the soldiers (during World War 2) in order to keep them awake. Later, in 1950s it was marketed as 'Benzedrine' for the people who want to lose weight. But now, it is that much common that sometimes the 'clandestine' laboratories are named as 'meth' i.e. 'meth labs'. It covers about 80-90 percent of total drug manufactured in clandestine laboratories (Hunt, Kuck, & Truitt, 2006).
The societal impact of clandestine laboratories in India is profound. Public health is severely compromised as these laboratories produce drugs with unknown purity and potency, leading to increased instances of overdoses, addiction, and drug-related fatalities (Freye, 2009). Environmental degradation is another significant issue, as the disposal of chemical waste from these laboratories contaminates soil and water resources, posing long-term ecological risks (EPA., 2009). Additionally, the illicit drug trade fuels organized crime and terrorism, destabilizing communities and undermining the rule of law (Asthana, 2010).
In response to the growing threat of clandestine laboratories, the Indian government has implemented several measures aimed at curbing this illegal activity. These include stricter regulations on the sale and distribution of precursor chemicals, enhanced surveillance and intelligence operations, and increased cooperation with international agencies to track and dismantle drug trafficking networks (Parmar, Narasimha, & Nath, 2024). Despite these efforts, significant challenges remain. The decentralized and covert nature of clandestine laboratories, combined with the sophisticated methods employed by traffickers, complicates enforcement efforts. Furthermore, legal loopholes and the need for inter-agency coordination continue to pose substantial hurdles (Cason, Fox, & Frank, 1980).
In India, there are several such labs busted or dismantled by narco-cops. Majority of such laboratories are established in southern part of India. Not only Indians but people from foreign countries are also convicted in such activities. In 2018, two Iranians convicted in the first meth labwf bust, were held by NCB in TN. Therefore, the proper identification and investigation of such labs is the key step for narco-cops to eradicate the huge problem of drug abuse in our country, this could be done by: Monitoring chemicals, Distribution control, Retail controls (as CMEA in U.S), Provide training, protect those who exposed to clandestine Labs, treating drug addiction, enforcing laws Prohibiting clandestine Lab operations (Cason et al., 1980). As these kinds of labs are the roots that provided, manufacture and supply (illegally) the controlled substances. Now, it is the necessity of time to eradicate such things and illegal activities to save our youth from being addict to such substances (MS Scott & Dedel, 2006). On the other hand, the criminal element found another way to illegally produce and sell the drugs on large scale this is done by illegal internet pharmacies, which operate without certification and prescribe drugs without adhering to legal guidelines or counterfeit medicines. This is much more difficult to counter this problem as the internet pharmacies are highly vulnerable and there is no specific guidelines for internet pharmacies more often they keep the identity of the organizers veiled (Fittler, Vida, Káplár, & Botz, 2018).
Also, this area also offers a keen research work including management of such illegal drug laboratories, several policies need to be made, extant of health and environmental effects, research could assist availability of raw material for such labs and should involve some remediation protocols (Clandestine Drug Laboratory: Remediation Guidelines, 2011).
Clandestine laboratories are the roots of another biggest problem i.e. drug addiction, money laundering etc. so in order to save future of our country strong rules and strategies should be made to completely remove this problem.
This research aims to provide a comprehensive analysis of the status of clandestine laboratories in India. By examining historical trends, current data, and enforcement strategies, the study seeks to identify the underlying factors contributing to the proliferation of these laboratories and evaluate the effectiveness of existing countermeasures. Additionally, the research will propose policy recommendations to enhance India's capacity to combat the illegal drug trade, thereby contributing to public health and national security.

Materials and Method

This research is based on the secondary data collected from various sources. The data used for the analysis were collected from the website of United Nations Office on Drugs and Crime (UNODC) and various newspapers published in the region of north India. The collected data was analyzed and visualized using the software OriginPro Learning Edition.

Result and Discussion

The collected data were analyzed, based on the different parameters which reveals the status of clandestine laboratories in India.

REDVET - Revista electrónica de Veterinaria - ISSN 1695-7504
Vol 25, No. 1 (2024)
http://www.veterinaria.org
Article Received: Revised: Accepted:



Figure 1. Distribution of Different End Products Produced by Clandestine Laboratories in India

Figure 1 illustrates that the highest number of clandestine laboratories in India are associated with the production of heroin (HO). This highlights a significant focus on manufacturing this particular CNS depressant, known for its high addiction potential and widespread abuse (Hung, 2024). Following heroin, methamphetamine (MPD) is the second most illegally produced drug. According to the latest data from the National Survey on Drug Use and Health, the 12-month prevalence of methamphetamine use among individuals aged 12 and above increased by 195% from its low in 2010 to 2018, underscoring its high illegal production globally (Paulus & Stewart, 2020).

After methamphetamine, Alprazolam (APZ) ranks third in illegal production in clandestine laboratories. Alprazolam, commonly prescribed for insomnia associated with various psychological disorders, is easily accessible due to its medical significance, leading to increased abuse (Huang, San, Liu, Zhu, & Xu, 2024).

In addition to these drugs, Ephedrine (EP) and unspecified methamphetamine (MDN) are also produced in significant quantities. Recent data indicates that authorities have dismantled eight clandestine laboratories producing MDN and seven producing EP in recent years.

Furthermore, the illegal production of Ketamine (KT), 3,4-Methylenedioxymethamphetamine (MDMA), and unspecified amphetamine (AMP) has been reported. In recent years, law enforcement has dismantled four, three, and two clandestine laboratories producing KT, MDMA, and AMP, respectively.

Figure 1 also depicts the recent increase in the demolition of clandestine laboratories involved in the illegal production of Fentanyl (FN), Lysergic acid diethylamide (LSD), Morphine (MO), Non-Descript Powdery Substance (NDPS), Synthetic Drugs (SD), Tramadol (TD), and the purest form of MDMA (MDMAP). This trend reflects enhanced efforts to combat the production of these highly potent and dangerous substances.

REDVET - Revista electrónica de Veterinaria - ISSN 1695-7504
Vol 25, No. 1 (2024)
http://www.veterinaria.org
Article Received: Revised: Accepted:



Figure 2. Number of clandestine laboratories demolished in India from 2011 to 2024

Figure 2 depicts the number of clandestine laboratories demolished in India from 2011 to 2024, categorized by the frequency of demolitions per year. The data is visually represented with three color codes: green for years with up to 5 demolished laboratories, orange for years with 6 to 10 demolished laboratories, and red for years with more than 10 demolished laboratories.

From 2011 to 2014, the number of demolished laboratories remained relatively low, fluctuating between 2 and 4. This period is represented by green bars, indicating fewer than 5 laboratories were demolished each year. In 2015, there was a noticeable increase, with the number of demolitions reaching 7, marked by an orange bar. This trend of increased demolitions continued, with a slight dip in 2016 but rising again to 7 by 2017.

The years 2018 and 2019 saw a decrease, with demolitions dropping back to 3 and 5 respectively, returning to the green category. However, starting from 2020, there was a significant upward trend. The number of demolished laboratories climbed steadily from 5 in 2020 to 10 in 2022, represented by orange bars.

The peak is observed in 2023, with a sharp increase to 14 demolished laboratories, marked by a red bar, indicating the highest number of demolitions within the analyzed period. This suggests a substantial escalation in efforts to identify and dismantle illegal drug production sites. In 2024 till month of march, the number of demolitions decreased again to 4, returning to the green category.



Figure 3. Distribution of clandestine laboratories in India based on the type of drug produced from 2011 to 2024

The pie chart in Figure 3 provides a clear visual representation of the distribution of clandestine laboratories based on the type of drug produced. Out of a total of 73 laboratories, 50.7% are involved in the production of depressants, 47.9% in stimulants, and a mere 1.4% in hallucinogenic drugs. This distribution underscores the predominant focus on depressants and stimulants in the illicit drug manufacturing landscape in India.

Table 1. Various drugs produced in clandestine laboratories categorized into stimulants, depressants, and hallucinogenic

Stimulant	Depressant	Hallucinogenic
Amphetamine	Alprazolam	LSD
Methamphetamine	Fentanyl	
Ephedrine	Ketamine	
Mephedrone	Tramadol	
MD Drug	Heroin	
	Morphine	

From 2011 to 2024, five stimulant drugs were frequently encountered in clandestine laboratories. These stimulants, known for their diverse pharmacological effects, primarily increase the activity of dopamine, norepinephrine, and serotonin in the brain. Although they have significant therapeutic uses, their potential for abuse and addiction poses considerable public health challenges.

Amphetamine, for example, is used medically to treat attention deficit hyperactivity disorder (ADHD) and narcolepsy. It increases the release of dopamine and norepinephrine in the brain, leading to enhanced central nervous system (CNS) activity. However, the abuse of amphetamine can lead to serious health issues, highlighting the need for careful regulation and monitoring (DAKIL & HASAN, 2024).

Similarly, methamphetamine is prescribed for attention deficient hyperactivity disorder (ADHD) and obesity but is commonly abused for its powerful stimulant effects. It increases the release and inhibits the reuptake of dopamine, resulting in high levels of this neurotransmitter in the brain. The effects of methamphetamine include intense euphoria, increased energy, and hyperactivity, but chronic use can result in severe psychological and physical health problems (Tok & Kesgin, 2024).

Ephedrine, another stimulant, is used as a decongestant, bronchodilator, and for treating hypotension during anesthesia. By stimulating adrenergic receptors, ephedrine causes the release of norepinephrine, leading to increased heart rate, blood pressure, and bronchodilation. Despite its medical benefits, misuse of ephedrine can cause significant health risks (Yan et al., 2024).

Mephedrone, primarily known as a recreational drug, is recognized for its euphoric effects but is illegal in many countries. It elevates levels of serotonin, dopamine, and norepinephrine in the brain, leading to euphoria, increased sociability, and energy. However, potential adverse effects, such as paranoia and anxiety, pose serious concerns (Kelečević et al., 2024).

MDMA, also used recreationally, is sought for its mood-enhancing and empathogenic effects. By increasing serotonin, dopamine, and norepinephrine levels in the brain, MDMA induces euphoria, emotional closeness, and enhanced sensory

REDVET - Revista electrónica de Veterinaria - ISSN 1695-7504
Vol 25, No. 1 (2024)
http://www.veterinaria.org
Article Received: Revised: Accepted:

perception. Nevertheless, risks such as dehydration, hyperthermia, and serotonin syndrome underscore the need for caution (van der Kolk et al., 2024).
In addition to stimulants, depressant drugs are also frequently encountered from clandestine laboratories. Depressants play a crucial role in managing various medical conditions, including anxiety, insomnia, pain, and seizures. However, their potential for abuse, dependence, and life-threatening side effects necessitates careful prescription and monitoring. Understanding the pharmacological mechanisms and effects of depressants is essential for optimizing their therapeutic use and mitigating associated risks.
For instance, alprazolam is widely prescribed for anxiety and panic disorders. As a benzodiazepine, it enhances the effect of GABA, an inhibitory neurotransmitter, leading to sedation, anxiety reduction, and muscle relaxation. Despite its therapeutic benefits, the potential for abuse and dependence requires careful management (Ait-Daoud, Hamby, Sharma, & Blevins, 2018).
Fentanyl is another depressant used for severe pain management, particularly in cancer patients and as an anesthetic. It binds to opioid receptors, producing powerful analgesic and euphoric effects. Although effective for pain relief and sedation, fentanyl's extreme potency carries a high risk of overdose, necessitating stringent control measures (Kuczyńska, Grzonkowski, Kacprzak, & Zawilska, 2018).
Ketamine, used for anesthesia and pain relief, is also being explored for treating depression. It acts as an NMDA receptor antagonist, reducing glutamate activity and leading to anesthesia, analgesia, and dissociative effects. The therapeutic potential of ketamine highlights the need for further research and controlled use (Sassano-Higgins, Baron, Juarez, Esmaili, & Gold, 2016).
Tramadol, prescribed for moderate to severe pain, is an opioid agonist that also inhibits the reuptake of norepinephrine and serotonin. Its use provides pain relief, sedation, and euphoria, but it also carries risks of dependence and abuse (Ahmed et al., 2018).
Heroin, an illegal opioid derived from morphine, is used for its intense euphoria and pain relief. Rapidly converted to morphine in the brain, it binds to opioid receptors, but its high potential for addiction and overdose presents severe public health challenges (O'Connor & McMahon, 2008).
Morphine itself is used medically for severe pain management. By binding to opioid receptors, it produces analgesia, providing pain relief and sedation. Despite its medical utility, the risk of addiction requires careful oversight (Vahedi, Hajebi, Vahidi, Nejati, & Saeedi, 2019).
Another significant category of drugs is hallucinogens, which offer a complex array of effects primarily through interactions with serotonin and glutamate receptors. While they hold promise for various therapeutic applications, their potential for psychological distress and perceptual disturbances necessitates careful management and further research.
Lysergic acid diethylamide (LSD) is used recreationally for its powerful hallucinogenic effects. It affects serotonin receptors, particularly 5-HT2A, altering thought processes, perceptions, and feelings, including visual hallucinations and an altered sense of time. The profound effects of LSD underscore the need for cautious use and further investigation into its therapeutic potential (Holze, Caluori, Vizeli, & Liechti, 2022).



Figure 4. Distribution of Clandestine Laboratories Involved in the Production of Synthetic and Semisynthetic Drugs from 2011 to 2024

REDVET - Revista electrónica de Veterinaria - ISSN 1695-7504
Vol 25, No. 1 (2024)
http://www.veterinaria.org
Article Received: Revised: Accepted:

Figure 4 demonstrates the two categories of drugs encountered in clandestine laboratories which are synthetic and semi-synthetic. The total number of laboratories identified is 73, with 42.5% involved in the production of synthetic drugs and 57.5% in the production of semi-synthetic drugs.

Table 2. Classification of Drugs Encountered in Clandestine Laboratories from 2011 to 2024 into Synthetic and Semi-Synthetic Types

Synthetic Drugs	Depressant
Alprazolam	Ephedrine
Amphetamine	Heroin
Fentanyl	LSD
Ketamine	Mephedrone
MD Drug	Morphine
Methamphetamine	
Tramadol	

The table 2 categorizes various drugs encountered in clandestine laboratories from 2011 to 2024 into synthetic and semi-synthetic types. Synthetic drugs include Alprazolam, Amphetamine, Fentanyl, Ketamine, MDMA, Methamphetamine, and Tramadol. Semi-synthetic drugs include Ephedrine, Heroin, LSD, Mephedrone, and Morphine.

Conclusion

The analysis of clandestine laboratories in India, based on various parameters, offers a comprehensive understanding of the current status and trends in illegal drug production. The findings indicate a significant prevalence of heroin production, underscoring its high addiction potential and widespread abuse. Methamphetamine and Alprazolam follow closely, reflecting their substantial illegal production due to their potent stimulant and depressant effects, respectively.

The data also reveals the persistent presence of other illicit drugs such as Ephedrine, Ketamine, MDMA, and various amphetamines, highlighting a diverse range of substances being manufactured illegally. The focus on both stimulants and depressants, with a minor presence of hallucinogens, indicates a targeted approach in the illicit drug market catering to different user needs.

The historical trend from 2011 to 2024 demonstrates fluctuating but generally increasing efforts in dismantling clandestine laboratories. A notable peak in demolitions was observed in 2023, indicating a significant escalation in law enforcement activities. This trend suggests enhanced vigilance and concerted efforts by authorities to curb illegal drug production.

Figures 3 and 4 further elucidate the distribution and types of drugs produced in these laboratories, with a predominant focus on depressants and stimulants. The classification into synthetic and semi-synthetic categories shows a substantial involvement in the production of both types, reflecting the adaptability and diversity of clandestine operations.

The data underscores the critical need for continued and enhanced efforts in combating clandestine drug production in India. The comprehensive understanding of production trends, types of drugs, and enforcement actions provides a strategic foundation for policymakers, law enforcement, and public health officials to devise targeted interventions and policies. These efforts are crucial for mitigating the public health impact and ensuring the safety and well-being of the population.

References

[1] Ahmed, A. I., El-Dawy, K., Fawzy, M. M., Abdallah, H. A., Elsaid, H. N. A., & Elmesslamy, W. O. (2018). Retrospective review of tramadol abuse.
[2] Ait-Daoud, N., Hamby, A. S., Sharma, S., & Blevins, D. (2018). A review of alprazolam use, misuse, and withdrawal. Journal of Addiction Medicine, 12, 4–10.
[3] Al-Obaidi, T. A., & Fletcher, S. M. (2014). Management of clandestine drug laboratories: Need for evidence-based environmental health policies. Environmental Health and Preventive Medicine, 19, 1–11.
[4] Asthana, V. (2010). Cross-border terrorism in India: Counterterrorism strategies and challenges. ACDIS Occasional Papers.
[5] Biswas, A., & Biswas, A. (2008). Small arms and drug trafficking in the Indian Ocean region. University of Mumbai.
[6] Broadhurst, R. (2018). Criminal innovation and illicit global markets-transnational crime in Asia. Australasian Policing, 10, 17–23.
[7] Buchanan, J. F., & Brown, C. R. (1988). 'Designer Drugs' A Problem in Clinical Toxicology. Medical Toxicology and Adverse Drug Experience, 3, 1–17.
[8] Buxton, J. (2008). The political economy of narcotics. The Political Economy of Narcotics, 1–257.
[9] Cason, T. A. D., Fox, R., & Frank, R. S. (1980). Investigations of clandestine drug manufacturing laboratories. Analytical Chemistry, 52, 804A-806A.
[10] Chiu, Y.-N., Leclerc, B., & Townsley, M. (2011). Crime script analysis of drug manufacturing in clandestine laboratories: Implications for prevention. The British Journal of Criminology, 51, 355–374.

[11] Clandestine drug laboratory: Remediation guidelines. (2011). Barton, Australia. Retrieved from http://www.ag.gov.au/Documents/2109 Remediation Guidelines_WEB.PDF
[12] Copes, R., & Dods, P. (2006). BC Centre for Disease Control Clandestine drug laboratories-public and environmental health aspects. BRITISH COLUMBIA MEDICAL JOURNAL, 48, 213.
[13] DAKIL, A. K., & HASAN, A. H. (2024). Impact of Amphetamine and Captagon abuse on the liver and renal function. Romanian JouRnal of Medical PRactice, 19, 98.
[14] EPA., U. S. (2009). Voluntary guidelines for methamphetamine laboratory cleanup. US EPA.
[15] Fittler, A., Vida, R. G., Káplár, M., & Botz, L. (2018). Consumers turning to the internet pharmacy market: cross-sectional study on the frequency and attitudes of Hungarian patients purchasing medications online. Journal of Medical Internet Research, 20, e11115.
[16] Freye, E. (2009). Pharmacology and Abuse of Cocaine, Amphetamines, Ecstasy and Related Designer Drugs: A comprehensive review on their mode of action, treatment of abuse and intoxication.
[17] Holze, F., Caluori, T. V, Vizeli, P., & Liechti, M. E. (2022). Safety pharmacology of acute LSD administration in healthy subjects. Psychopharmacology, 1–13.
[18] Huang, F., San, X., Liu, Q., Zhu, H., & Xu, W. (2024). Signal mining and risk analysis of Alprazolam adverse events based on the FAERS database. Scientific Reports, 14, 7489.
[19] Hung, J. (2024). Drug Abuse. In Left-Behind Children’s Juvenile Delinquency and Substance Abuse in China: Policy Examination and Analysis (pp. 85–101). Springer.
[20] Hunt, D. E., Kuck, S., & Truitt, L. (2006). Methamphetamine use: Lessons learned. Abt Associates Cambridge, MA.
[21] India, G. of. NDPS 1985.
[22] Kelečević, I., Vejnović, A.-M., Javorac, J., Gvozdenović, N., Janjić, N., & Mijatović Jovin, V. (2024). Metaphedrone (3-Methylmethcathinone): Pharmacological, Clinical, and Toxicological Profile. Medicina, 60, 466.
[23] Kuczyńska, K., Grzonkowski, P., Kacprzak, Ł., & Zawilska, J. B. (2018). Abuse of fentanyl: An emerging problem to face. Forensic Science International, 289, 207–214.
[24] Lalitha, N. (2002). Indian pharmaceutical industry in WTO regime: a SWOT analysis. Economic and Political Weekly, 3542–3555.
[25] Laura Bruck. (2007, September). Methamphetamine: Recipe for Disaster. EHS Today. Retrieved from https://www.ehstoday.com/emergency-management/article/21907378/methamphetamine-recipe-for-disaster
[26] Lyman, M. D. (2016). Drugs in society: Causes, concepts, and control. Routledge.
[27] Man, G., Stoeber, B., Walus, K., & Columbia, U. of B. (2008). Detecting and identifying clandestine drug laboratories: sensing technology assessment. Canadian Police Research Centre= Centre Canadien de recherches policières.
[28] MS Scott, & Dedel, K. Community Oriented Policing Service U.S Department of Justice Clandestine Methamphetamine Laboratories 2nd Edition. , (2006).
[29] O’Connor, G., & McMahon, G. (2008). Complications of heroin abuse. European Journal of Emergency Medicine, 15, 104–106.
[30] Parmar, A., Narasimha, V. L., & Nath, S. (2024). National drug laws, policies, and programs in India: A narrative review. Indian Journal of Psychological Medicine, 46, 5–13.
[31] Paulus, M. P., & Stewart, J. L. (2020). Methamphetamine use disorder: the next addiction crisis. JAMA Psychiatry, 77, 959.
[32] Sassano-Higgins, S., Baron, D., Juarez, G., Esmaili, N., & Gold, M. (2016). A review of ketamine abuse and diversion. Depression and Anxiety, 33, 718–727.
[33] Singer, M. (2008). Drugs and development: the global impact of drug use and trafficking on social and economic development. International Journal of Drug Policy, 19, 467–478.
[34] Tok, H. H., & Kesgin, M. T. (2024). Systematic review; reasons for using methamphetamine: Systematic review. Archives of Psychiatric Nursing.
[35] Vahedi, H. S. M., Hajebi, H., Vahidi, E., Nejati, A., & Saeedi, M. (2019). Comparison between intravenous morphine versus fentanyl in acute pain relief in drug abusers with acute limb traumatic injury. World Journal of Emergency Medicine, 10, 27.
[36] van der Kolk, B. A., Wang, J. B., Yehuda, R., Bedrosian, L., Coker, A. R., Harrison, C., … Doblin, R. (2024). Effects of MDMA-assisted therapy for PTSD on self-experience. PLoS One, 19, e0295926.
[37] Wright, J., Edwards, J., & Walker, S. (2016). Exposures associated with clandestine methamphetamine drug laboratories in Australia. Reviews on Environmental Health, 31, 329–352.
[38] Yan, H. U., Mengqing, W., Jing, X. I. E., Luojia, J., Yi, D., & Yinhe, L. U. O. (2024). Exposure to ephedrine attenuates Th1/Th2 imbalance underlying OVA-induced asthma through airway epithelial cell-derived exosomal lnc-TRPM2-AS. Chinese Journal of Natural Medicines, 22, 530–540.